China's NMPA Grants Breakthrough Therapy Designation for Anti-CTLA-4 Antibody Candidate Gotistobart (BNT316/ONC-392) - Thailand PR News - [Banking](https://thailandbusinessnews.net/category/banking/) - [Companies](https://thailandbusinessnews.net/category/companies/) - [Economy](https://thailandbusinessnews.net/category/economy/) - [Press Releases](https://thailandbusinessnews.net/category/press-release/) - [PR Newswire](https://thailandbusinessnews.net/pr-newswire-updates/) - [Tech](https://thailandbusinessnews.net/category/tech/) - [Tourism](https://thailandbusinessnews.net/category/tourism/) - [Press Release](https://thailandbusinessnews.net/category/press-release/) # China's NMPA Grants Breakthrough Therapy Designation for Anti-CTLA-4 Antibody Candidate Gotistobart (BNT316/ONC-392) ##### Up next ![Daewoong Pharmaceutical: Third IDMC Reaffirms Safety of Bersiporocin and Recommends Continuation of Global Phase 2 Clinical Trial](https://i0.wp.com/r2.thailandbusinessnews.net/2025/10/Daewoong_Pharmaceutical_image.jpg?resize=200%2C110&ssl=1 "Daewoong Pharmaceutical: Third IDMC Reaffirms Safety of Bersiporocin and Recommends Continuation of Global Phase 2 Clinical Trial") [](https://thailandbusinessnews.net/press-release/daewoong-pharmaceutical-third-idmc-reaffirms-safety-of-bersiporocin-and-recommends-continuation-of-global-phase-2-clinical-trial/) ###### [Daewoong Pharmaceutical: Third IDMC Reaffirms Safety of Bersiporocin and Recommends Continuation of Global Phase 2 Clinical Trial](https://thailandbusinessnews.net/press-release/daewoong-pharmaceutical-third-idmc-reaffirms-safety-of-bersiporocin-and-recommends-continuation-of-global-phase-2-clinical-trial/) Published on 27 October 2025 ##### Author ##### [ CISION PRNewswire ](https://thailandbusinessnews.net/author/cision/) ##### Tags - [PRNewswire](https://thailandbusinessnews.net/tag/prnewswire/) ![](https://mma.prnasia.com/media2/2787251/OncoC4_Logo.jpg?p=medium600 "logo") Designation granted for gotistobart (BNT316/ONC392) for the treatment of patients with squamous non-small cell lung cancer (sqNSCLC), an aggressive subtype of lung cancer Breakthrough Therapy designation will allow for an expedited development and regulatory review of gotistobart in China Global pivotal PRESERVE-003 Phase 3 clinical trial in squamous non-small cell lung cancer Is Ongoing ROCKVILLE, Md., Oct. 27, 2025 /PRNewswire/ — OncoC4 announced today that China’s National Medical Product Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for gotistobart (BNT316/ONC392) for the treatment of patients with squamous non-small cell lung cancer (sqNSCLC) who have progressed on prior standard immuno-oncology therapies (IO). Gotistobart is a next-generation anti-CTLA-4 antibody candidate which is being jointly developed by BioNTech and OncoC4. Squamous non-small cell lung cancer (sqNSCLC) is an aggressive subtype of lung cancer accounting for approximately 25-30% of all NSCLC cases, the most common type of lung cancer1. The 5-year relative survival rate for patients with sqNSCLC is 15%2. While novel first line treatments combining immune-checkpoint inhibition and chemotherapy have improved outcomes of patients with NSCLC, the medical need remains high for novel treatments options, especially for patients with lung cancer that have progressed on first-line therapy and have limited treatment options3. "For the past 5 years, limited advances in treatment outcomes have been reported for EGFR wild-type NSCLC patients who progressed on the first-line IO and chemotherapies. We believe gotistobart has the potential to broaden the reach of CTLA-4-targeting immunotherapy and to improve outcomes for patients living with sqNSCLC." said Pan Zheng, MD, PhD, Co-founder and Chief Medical Officer of OncoC4. "Gotistobart is a next-gen acid pH-sensitive anti-CTLA4 mAb that conferred an improved therapeutic index compared with approved anti-CTLA-4 antibodies by preserving CTLA-4 on regulatory T cells as demonstrated in preclinical models. The emerging data support clinical proof of concept for this new approach", added Yang Liu, PhD, Co-Founder, Chief Executive Officer, and Chief Scientific Officer of OncoC4. Gotistobart is currently being evaluated in a registrational two-stage randomized Phase 3 trial, PRESERVE-003 (NCT05671510). The clinical trial assesses the efficacy and safety of gotistobart as monotherapy compared to the standard-of-care chemotherapy (docetaxel) in patients with metastatic sqNSCLC that progressed under previous PD-(L)1-inhibitor treatment. The initiation of the Phase 3 trial was based on positive safety and efficacy data from an ongoing Phase 1/2 trial (NCT04140526) with gotistobart alone and in combination with pembrolizumab in patients with advanced solid tumors. The program received Fast Track Designation from the U.S. Food and Drug Administration (FDA) in 2022 and represents an innovative approach which aims to leverage the full potential of CTLA-4-targeting therapies. Breakthrough Therapy Designation is an NMPA program designed to expedite the development and regulatory review of investigational therapies that are designed to address serious or life-threatening conditions. To receive the designation, the candidate needs to demonstrate preliminary clinical evidence that indicates that it may offer substantial improvement over existing therapies on one or more clinically significant endpoints. The NMPA’s BTD designation is based on the Stage 1 safety and efficacy data of the PRESERVE-003 trial. The detailed data will be reported in an upcoming medical conference in December 2025. With the Breakthrough Therapy designation, the development of gotistobart may benefit from more frequent engagement with the NMPA, which will support the collection of appropriate data needed to accelerate development and may also allow for priority review if the relevant criteria are met. About PRESERVE-003 The two-stage, open-label, randomized Phase 3 trial, PRESERVE-003 (NCT05671510), will assess the efficacy and safety of gotistobart (BNT316/ONC-392) as monotherapy compared to the standard-of-care chemotherapy (docetaxel) in patients with metastatic NSCLC that progressed under previous PD-(L)1-inhibitor treatment. Stage 1, the non-pivotal dose-confirmation stage, assessed the efficacy and safety of two gotistobart dosing regimens in comparison to docetaxel in patients with squamous and non-squamous non-small cell lung cancer (NSCLC). Stage 2 is the pivotal stage of the trial and will assess the safety and efficacy of gotistobart in squamous cell NSCLC. The primary endpoint measure is overall survival. Secondary endpoints include overall response rate, progression-free survival and adverse event profile. Approximately 600 patients are planned to be enrolled at clinical sites in 12 countries and regions globally, including China, Germany, Italy, South Korea, Türkiye, the United Kingdom, and the United States. About gotistobart (BNT316/ONC392) Gotistobart is licensed to BioNTech for commercialization and jointly developed clinically by OncoC4 and BioNTech for oncology indications. There are several ongoing clinical trials in different tumor types, investigating gotistobart either as monotherapy or in combination with other therapeutic agents. About OncoC4 Based in Rockville, Maryland, OncoC4 is a privately held, late-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologicals for the treatment of cancer and immunological diseases. OncoC4’s pipeline features assets with first-in-class and best-in-class potential targeting both novel and well validated targets across oncology and immunological diseases. Among them, AI-081 is a fully owned and potentially best-in-class bispecific antibody candidate targeting PD-1 and VEGF. AI-081 is currently enrolling patients in a Phase 2 trial that could enable two or more pivotal studies. ONC-841 is a first-in-class anti-SIGLEC10 antibody currently in a Phase 2 trial for oncology indications and being explored for neurodegenerative diseases. OncoC4 has a strategic collaboration with BioNTech to co-develop gotistobart (BNT316/ONC-392), a next-generation anti-CTLA-4 antibody candidate, in multiple solid tumor indications, including an ongoing pivotal clinical trial in squamous non-small cell lung cancer. More information: [www.oncoc4.com](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4541790-1&h=1508445533&u=http%3A%2F%2Fwww.oncoc4.com%2F&a=www.oncoc4.com). Investor Contact:Ryan Cui, Executive Director of Investor Relations 1 Houston KA, Henley SJ, Li J, White MC and Richards TB, Lung Cancer, 86:22-28, 2014.2 Hu S, Zhang W, Guo Q, Ye J, Zhang D, Zhang Y, Zeng W, Yu D, Peng J, Wei Y, Xu J, International Journal of General Medicine, 14:9567-9588.3 Lau SCM, Pan Y, Velcheti V and Wong K, Cancer Cell, 40:1279-1293, 2022. [Source link ](https://www.prnasia.com/story/archive/4807342_AE07342_0?rand=89749) ``` This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network ``` ##### You May Also Like [](https://thailandbusinessnews.net/press-release/coco-bubble-tea-announces-new-openings-in-southeast-asia/) ![CoCo Bubble Tea Announces New Openings in Southeast Asia](https://i0.wp.com/r2.thailandbusinessnews.net/2025/04/Cambodia_0.jpg?resize=260%2C140&ssl=1 "CoCo Bubble Tea Announces New Openings in Southeast Asia") - [Press Release](https://thailandbusinessnews.net/category/press-release/) ## CoCo Bubble Tea Announces New Openings in Southeast Asia Leading boba brand to open stores in Kuala Lumpur and Phnom Penh,… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - April 30, 2025 [](https://thailandbusinessnews.net/press-release/pr-newswire-leads-in-seo-and-ai-search-drives-double-the-ai-mentions-of-competitors/) ## PR Newswire Leads in SEO and AI Search, Drives Double the AI Mentions of Competitors HONG KONG, Nov. 13, 2025 /PRNewswire/ — PR Newswire is unveiling independent… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - November 13, 2025 [](https://thailandbusinessnews.net/press-release/hindustan-zinc-beats-consensus-backed-by-all-time-high-silver-prices-and-first-quarter-lowest-cost-of-production/) ![Hindustan Zinc beats consensus, backed by all-time high silver prices and first quarter lowest cost of production](https://i0.wp.com/r2.thailandbusinessnews.net/2025/07/Hindustan_Zinc.jpg?resize=260%2C140&ssl=1 "Hindustan Zinc beats consensus, backed by all-time high silver prices and first quarter lowest cost of production") - [Press Release](https://thailandbusinessnews.net/category/press-release/) ## Hindustan Zinc beats consensus, backed by all-time high silver prices and first quarter lowest cost of production UDAIPUR, India, July 21, 2025 /PRNewswire/ — India-based Hindustan Zinc Limited, a… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - July 21, 2025 ##### Most Read - [![Priority Pass to accelerate travel innovation, backed by the Collinson Group's £500 million growth programme](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/priority-pass-to-accelerate-travel-innovation-backed-by-the-collinson-groups-500-million-growth-programme-2/ "Priority Pass to accelerate travel innovation, backed by the Collinson Group's £500 million growth programme") [Priority Pass to accelerate travel innovation, backed by the Collinson Group's £500 million growth programme](https://thailandbusinessnews.net/press-release/priority-pass-to-accelerate-travel-innovation-backed-by-the-collinson-groups-500-million-growth-programme-2/ "Priority Pass to accelerate travel innovation, backed by the Collinson Group's £500 million growth programme") - [![IMG Completes Acquisition of World Nomads, Expanding Global Travel Insurance Distribution](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/img-completes-acquisition-of-world-nomads-expanding-global-travel-insurance-distribution/ "IMG Completes Acquisition of World Nomads, Expanding Global Travel Insurance Distribution") [IMG Completes Acquisition of World Nomads, Expanding Global Travel Insurance Distribution](https://thailandbusinessnews.net/press-release/img-completes-acquisition-of-world-nomads-expanding-global-travel-insurance-distribution/ "IMG Completes Acquisition of World Nomads, Expanding Global Travel Insurance Distribution") - [![Modern Meadow and Bellroy Partner on Carry Products Made of Next-Generation Material](https://i0.wp.com/r2.thailandbusinessnews.net/2025/04/MODERN_MEADOW_LOGO_BLACK_PNG_Logo.jpg?fit=597%2C138&ssl=1&resize=40%2C40)](https://thailandbusinessnews.net/press-release/modern-meadow-and-bellroy-partner-on-carry-products-made-of-next-generation-material/ "Modern Meadow and Bellroy Partner on Carry Products Made of Next-Generation Material") [Modern Meadow and Bellroy Partner on Carry Products Made of Next-Generation Material](https://thailandbusinessnews.net/press-release/modern-meadow-and-bellroy-partner-on-carry-products-made-of-next-generation-material/ "Modern Meadow and Bellroy Partner on Carry Products Made of Next-Generation Material") - [![DORCO Wins 2026 Red Dot Award for Renewed Corporate Identity](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/dorco-wins-2026-red-dot-award-for-renewed-corporate-identity/ "DORCO Wins 2026 Red Dot Award for Renewed Corporate Identity") [DORCO Wins 2026 Red Dot Award for Renewed Corporate Identity](https://thailandbusinessnews.net/press-release/dorco-wins-2026-red-dot-award-for-renewed-corporate-identity/ "DORCO Wins 2026 Red Dot Award for Renewed Corporate Identity") - [![Tamarind Health launches Rare Cancer Centre to make specialist expertise easier to access](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/tamarind-health-launches-rare-cancer-centre-to-make-specialist-expertise-easier-to-access/ "Tamarind Health launches Rare Cancer Centre to make specialist expertise easier to access") [Tamarind Health launches Rare Cancer Centre to make specialist expertise easier to access](https://thailandbusinessnews.net/press-release/tamarind-health-launches-rare-cancer-centre-to-make-specialist-expertise-easier-to-access/ "Tamarind Health launches Rare Cancer Centre to make specialist expertise easier to access") - [![MemoMind One Rolls Out New Features and Prepares for a New Stage of Developer Access](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/memomind-one-rolls-out-new-features-and-prepares-for-a-new-stage-of-developer-access/ "MemoMind One Rolls Out New Features and Prepares for a New Stage of Developer Access") [MemoMind One Rolls Out New Features and Prepares for a New Stage of Developer Access](https://thailandbusinessnews.net/press-release/memomind-one-rolls-out-new-features-and-prepares-for-a-new-stage-of-developer-access/ "MemoMind One Rolls Out New Features and Prepares for a New Stage of Developer Access") ##### Subscribe via Email Enter your email address to subscribe and receive notifications of new posts by email. Email Address Subscribe [](https://thailandbusinessnews.net/press-release/discovering-indonesia-through-experiences-beyond-the-ordinary/) ![Discovering Indonesia Through Experiences Beyond the Ordinary](https://i0.wp.com/mmx.prnasia.com/media/MS2001398/20260930223712EDT_image_1.jpg?resize=260%2C140&ssl=1 "Discovering Indonesia Through Experiences Beyond the Ordinary") ## Discovering Indonesia Through Experiences Beyond the Ordinary SEOUL, South Korea, Oct. 2, 2026 /PRNewswire/ —… [](https://thailandbusinessnews.net/press-release/vestas-powers-up-vietnams-clean-energy-ambitions-with-two-new-projects-under-pdp8-totaling-16-wind-turbines/) ![Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines](https://i0.wp.com/mmx.prnasia.com/media/MS2001368/20261002002233EDT_image_2.jpg?resize=260%2C140&ssl=1 "Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines") ## Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines HANOI, Vietnam, Oct. 2, 2026 /PRNewswire/ — Vestas has been awarded contracts… [](https://thailandbusinessnews.net/press-release/iqiyi-aigc-series-the-ferry-man-exceeds-rmb-8-million-in-revenue-sharing-as-third-instalment-debuts-on-october-1/) ![iQIYI AIGC Series "The Ferry Man" Exceeds RMB 8 Million in Revenue-Sharing as Third Instalment Debuts on October 1](https://i0.wp.com/mmx.prnasia.com/media/MS2001352/20261001223355EDT_image_1.jpg?resize=260%2C140&ssl=1 "iQIYI AIGC Series "The Ferry Man" Exceeds RMB 8 Million in Revenue-Sharing as Third Instalment Debuts on October 1") ## iQIYI AIGC Series "The Ferry Man" Exceeds RMB 8 Million in Revenue-Sharing as Third Instalment Debuts on October 1 BEIJING, Oct. 2, 2026 /PRNewswire/ — iQIYI, China’s leading online… [](https://thailandbusinessnews.net/press-release/ifs-capital-signs-inaugural-msme-loan-securitisation-programme/) ## IFS Capital signs inaugural MSME loan securitisation programme S$79 million securitisation transaction backed by a portfolio of MSME loans secured…